Merus BV Financials

MRUS Stock  USD 47.22  0.12  0.25%   
Based on the key indicators related to Merus BV's liquidity, profitability, solvency, and operating efficiency, Merus BV may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, Merus BV's Liabilities And Stockholders Equity is comparatively stable compared to the past year. Property Plant And Equipment Gross is likely to gain to about 31 M in 2025, despite the fact that Other Current Liabilities is likely to grow to (12.5 M). Key indicators impacting Merus BV's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio33.3631.7758
Sufficiently Up
Slightly volatile
The financial analysis of Merus BV is a critical element in measuring its lifeblood. Investors should not minimize Merus BV's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.

Net Income

(204.56 Million)

  
Please note, the imprecision that can be found in Merus BV's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Merus BV. Check Merus BV's Beneish M Score to see the likelihood of Merus BV's management manipulating its earnings.

Merus BV Stock Summary

Merus BV competes with Anebulo Pharmaceuticals, Adagene, Acrivon Therapeutics,, AnaptysBio, and Mineralys Therapeutics,. Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. Merus NV is traded on NASDAQ Exchange in the United States.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINNL0011606264
CUSIPN5749R100
LocationNetherlands
Business AddressUppsalalaan 17, Utrecht,
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.merus.nl
Phone31 30 253 8800
CurrencyUSD - US Dollar

Merus BV Key Financial Ratios

Merus BV Key Balance Sheet Accounts

202020212022202320242025 (projected)
Total Assets231.2M456.6M376.5M455.5M782.7M821.8M
Other Current Liab21.8M22.5M35.6M38.5M(13.2M)(12.5M)
Net Debt(159.1M)(237.7M)(134.3M)(192.9M)(283.4M)(269.2M)
Retained Earnings(400.1M)(466.9M)(598.1M)(753.1M)(968.4M)(920.0M)
Accounts Payable3.1M13.2M9.8M4.6M4.2M4.7M
Cash163.1M241.4M147.7M205.0M293.3M308.0M
Net Receivables1.7M6.7M4.7M4.0M1.3M1.2M
Total Liab129.0M140.4M129.5M99.2M134.8M97.7M
Total Current Assets218.0M424.2M306.4M368.8M569.1M597.5M
Short Term Debt1.4M1.5M1.7M1.7M1.7M1.7M
Common Stock3.2M4.5M4.8M5.9M7.0M7.3M
Net Tangible Assets128.4M99.4M313.9M245.1M281.9M296.0M
Other Current Assets8.5M7.1M11.5M9.7M27.3M28.7M
Intangible Assets2.8M2.3M2.0M1.8M1.7M1.7M
Other Liab91.4M79.7M66.2M38.8M44.6M64.7M
Other Assets2.4M2.5M6.9M(3M)(538.7M)(511.8M)
Inventory1.07.4M4.9M9.3M1.151.09

Merus BV Key Income Statement Accounts

The reason investors look at the income statement is to determine what Merus BV's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
202020212022202320242025 (projected)
Interest Expense18.6M129K2.7M14.5M30.8M32.3M
Total Revenue29.9M49.1M41.6M43.9M36.1M26.4M
Gross Profit(27.4M)(37.2M)29.6M43.9M36.1M37.9M
Operating Income(75.9M)(90.0M)(160.0M)(156.5M)(272.1M)(258.5M)
Ebit(62.4M)(79.2M)(149.5M)(156.5M)(272.1M)(258.5M)
Ebitda(60.9M)(77.7M)(148.3M)(154.0M)(269.6M)(256.1M)
Cost Of Revenue57.3M86.3M12.0M127.4M146.5M153.8M
Income Before Tax(85.0M)(66.6M)(130.2M)(151.7M)(207.2M)(196.8M)
Net Income(85.5M)(66.8M)(131.2M)(154.9M)(215.3M)(204.6M)
Income Tax Expense503K239K959K3.2M8.2M8.6M
Research Development70.0M98.2M149.4M140.7M225.4M236.6M
Interest Income2.1M1.9M300K2.7M3.1M3.3M
Tax Provision503K239K959K2.5M8.2M8.6M
Net Interest Income300K(129K)2.7M10.7M30.8M32.3M

Merus BV Key Cash Accounts

202020212022202320242025 (projected)
Change In Cash(34.5M)78.5M(93.3M)56.6M89.0M93.5M
Free Cash Flow(81.2M)(60.5M)(157.5M)(146.2M)(187.5M)(178.1M)
Depreciation1.4M1.5M1.3M2.5M2.5M2.6M
Other Non Cash Items9.0M(27.3M)(23.9M)8.9M(42.8M)(40.7M)
Capital Expenditures1.3M870K7.6M4.0M1.7M2.2M
Net Income(85.5M)(66.8M)(131.2M)(154.9M)(215.3M)(204.6M)
End Period Cash Flow163.3M241.7M148.4M205.0M294.0M156.5M
Change To Netincome6.1M18.2M(10.2M)(1.0M)(921.6K)(875.5K)
Change To Inventory(743.5K)2.3M4.1M1.0M1.2M1.9M
Investments(1.5M)(146.6M)2.8M(24.0M)(220.2M)(209.2M)

Merus Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Merus BV's current stock value. Our valuation model uses many indicators to compare Merus BV value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Merus BV competition to find correlations between indicators driving Merus BV's intrinsic value. More Info.
Merus BV is regarded fourth in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Merus BV's Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Merus BV by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Merus BV Systematic Risk

Merus BV's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Merus BV volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was five with a total number of output elements of fifty-six. The Beta measures systematic risk based on how returns on Merus BV correlated with the market. If Beta is less than 0 Merus BV generally moves in the opposite direction as compared to the market. If Merus BV Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Merus BV is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Merus BV is generally in the same direction as the market. If Beta > 1 Merus BV moves generally in the same direction as, but more than the movement of the benchmark.

Merus BV Thematic Clasifications

Merus BV is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
Pharmaceutical ProductsView
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Today, most investors in Merus BV Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Merus BV's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Merus BV growth as a starting point in their analysis.

Price Earnings To Growth Ratio

(1.02)

At this time, Merus BV's Price Earnings To Growth Ratio is comparatively stable compared to the past year.

Merus BV March 18, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Merus BV help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Merus BV. We use our internally-developed statistical techniques to arrive at the intrinsic value of Merus BV based on widely used predictive technical indicators. In general, we focus on analyzing Merus Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Merus BV's daily price indicators and compare them against related drivers.

Additional Tools for Merus Stock Analysis

When running Merus BV's price analysis, check to measure Merus BV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merus BV is operating at the current time. Most of Merus BV's value examination focuses on studying past and present price action to predict the probability of Merus BV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merus BV's price. Additionally, you may evaluate how the addition of Merus BV to your portfolios can decrease your overall portfolio volatility.